ERBB2 and breast cancer: Seventy-seven consecutive patients diagnosed with HER2+ advanced BC and treated with T-DM1 at Hospital Clínic of Barcelona (HCB) and Istituto Oncologico Veneto (IOV) in Padova were evaluated.